Lilly acquires Calytrix Bio
Statements (7)
- Bullish
Eli Lilly is acquiring Calytrix Bio for up to $1.5 billion
- Bullish
Lilly acquired startup Calytrix for $1.5 billion to develop a therapy for rare blood disorders.
- Bullish
Eli Lilly has acquired Calytrix Bio for up to $1.5 billion.
- Bullish
Calytrix Bio is being acquired by Eli Lilly for up to $1.5 billion in cash
- Bullish
Lilly agrees to buy Calytrix Bio for up to $1.5 billion
- Neutral
Eli Lilly is acquiring biotech firm Calytrix Bio for a deal that will allow Eli Lilly to expand its biotechnology operations
- Neutral
Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis.